MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jns.2026.126092

Медицинская библиотека · Journal of the neurological sciences · 2026

Long-term treatment with Eptinezumab in special treatment situations: Real world data.

Höfer Berit, Koschatzky Klaus, Sabatowski Rainer, Koch Thea, Klimova Anna, Gossrau Gudrun

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The neurotransmitter Calcitonin Gene related Peptide (CGRP) is one of the key players driving migraine attacks. Randomized placebo-controlled studies with eptinezumab, a humanized monoclonal IgG1 antibody directed against CGRP, provided evidence for its migraine prophylactic effects. This study shows real-world data on eptinezumab in patients with episodic (eM) and chronic migraine (cM) investigating 3 to 12 months of treatment duration.

METHODS

Patients were treated with eptinezumab 100 mg i.v. every 12 weeks for up to 12 months. Clinical data and reports of monthly headache days (MHD), monthly analgesic days (MAD), mean monthly headache intensity (MHI) were collected at baseline (BL) and at month 1 to 12 (M1 to M12) of eptinezumab therapy.

RESULTS

46 patients (mean 46 ± 12.5 years, 37 females) were included (17 eM, 29 cM). 53% with comorbid psychiatric disorder, 45% with additional pain syndromes, 84% failed at least one CGRP (R) mAb, 92% amitriptyline, 82% topiramate, 76% betablockers, 59% onabotulinumtoxin A, 41% flunarizine. Mean MHD dropped significantly after the 1st, 2nd and 3rd eptinezumab infusion (BL 15.5 ± 1.1; M1 12.1 ± 1.3, p ≤ 0.0001; M4 10.1 ± 1.3, p ≤ 0.0003; M7 9.0 ± 1.6; p ≤ 0.007). Mean MAD (BL 9.2 ± 4.3; M7 4.9 ± 2.8, p ≤ 0.038) and mean MHI (BL 7 ± 1.8; M7 4.9 ± 1.9, p < 0.0001) were significantly reduced following eptinezumab.

CONCLUSIONS

Eptinezumab real-world data demonstrate significant effects on monthly headache days, analgesic days and headache intensity in patients with migraine with multiple prophylactic therapy failures and concomitant depression or other pain disorders.

Для цитирования: Höfer Berit, Koschatzky Klaus, Sabatowski Rainer, Koch Thea, Klimova Anna, Gossrau Gudrun. Long-term treatment with Eptinezumab in special treatment situations: Real world data.. Journal of the neurological sciences. 2026. DOI: 10.1016/j.jns.2026.126092.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.